Redefining the discovery and development of best-in-class oligonucleotide therapeutics

Our Mission

With OligoCreator, our AI-empowered drug discovery platform, we deliver on our mission to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.

About Us

We develop cutting-edge oligonucleotide therapies, that go beyond the reach of existing treatments and offer new hope to patients around the world.

Our Science

OligoCreator, our AI-empowered drug discovery platform, combines both innovative and proven delivery modalities with the precision and specificity of oligonucleotides.

Partnering

Global partner of choice for oligonucleotide drug discovery and development programs.

Pipeline

Innovative treatment options for indications where oligonucleotide-based therapeutics have the potential to be first-in-class or best-in-class.

About us

We redefine the discovery and development of best-in-class oligonucleotide therapeutics. With our AI-empowered OligoCreator platform, which integrates a variety of delivery technologies, we identify and characterize oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By precisely delivering these novel therapeutics to specific cells, organs or tissues, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Our unique OligoCreator platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.

Latest News & Events

all news

all events

October 31, 2024

Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Officer

Martinsried (Munich), Germany, October 31, 2024 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the promotion of Konstantin Petropoulos, PhD, MBA, to Chief Executive Officer. He has served as the Company’s Chief Business Officer since June 2023. Alexander Gebauer, MD, PhD, is stepping down with immediate effect to focus his efforts on another company, Galimedix Therapeutics, that he has co-founded and is leading. He will continue to support Dr. Petropoulos in his new role to ensure a smooth transition.

September 09, 2024

Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3

NLRP3 is a promising target with a well-validated role in various inflammatory disease
Secarna has shown the potential of the company’s ASOs to effectively and specifically suppress NLRP3 and IL-1β release
In a CAPS mouse model, Secarna demonstrated prolonged survival and a significant reduction in systemic inflammation

September 04, 2024

Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius

Scientific Advisory Board (SAB) to offer expert guidance and direction for the development of lead compound SECN-15 and the Company’s oncology pipeline
Dr. Alexander M.M. Eggermont convened SAB as of July 1, 2024 together with Prof. Dr. Alfred Zippelius, who has been an advisor to Secarna since 2016

With our AI-empowered OligoCreator platform we streamline the identification and characterization of best-in-class oligonucleotide therapies to deliver transformative treatments and hope to patients in need by pushing the boundaries of medical science and transforming lives for the better.

Konstantin Petropoulos, Ph.D., MBA
CEO